Working... Menu
Trial record 1 of 112 for:    acyclovir
Previous Study | Return to List | Next Study

A Clinical Trial of Acyclovir for Viral Uveitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03389191
Recruitment Status : Recruiting
First Posted : January 3, 2018
Last Update Posted : January 3, 2018
Information provided by (Responsible Party):
Xiaomin Zhang, Tianjin Medical University

Brief Summary:
This project is designed to test the hypothesis that acyclovir is clinically useful for patients with refractory viral uveitis.

Condition or disease Intervention/treatment Phase
Uveitis Drug: Acyclovir Not Applicable

Detailed Description:

Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the study design, aims, benefits and potential risks. This is a prospective non-comparative interventional study.

Aqueous humor samples were collected from participants to virus detection. Participants will take oral acyclovir 100 mg three times a day and data will be collected prospectively with regard to ophthalmologic outcomes. Study participants will be followed for up to 12 months to determine efficacy, and an additional 30 days for safety reports. Descriptive statistics will be gathered on participant demographics, uveitis characteristics, change in immunosuppressive medications, number of responders, ophthalmologic measures and change in corticosteroid dose during the study period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Trial of Oral Acyclovir in Viral Uveitis
Actual Study Start Date : January 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Patients with Viral Uveitis
Oral acyclovir 100 mg three times a day (TID).
Drug: Acyclovir

Primary Outcome Measures :
  1. Global assessment of ocular status [ Time Frame: 12 weeks ]
    Global assessment of ocular status

Secondary Outcome Measures :
  1. Best Corrected Visual Acuity in logMAR [ Time Frame: 12 weeks ]
    Best Corrected Visual Acuity in logMAR

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Age between 18 and above. 2. Chronic, vision threatening viral uveitis. 3. Patients can't tolerate hormone therapy bacause of drug side effects. 4. Consent to undergo anterior chamber tap and give aqueous for the study. 5. Able to undergo relevant tests. 6. Able to come for subsequent follow-up visits. 7. Ability to provide informed consent.

Exclusion Criteria:

  • 1. Patients who are allergic to ayclovir. 2. Immunocompromised patients 3. Positive for HIV, Hep B and Hep C 4. Not keen on participating in the study 5. Patients who are incapable, either by law or mental state, of giving consents in their own right.

    6. Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol.

    7. Patients who are pregnant or breastfeeding. 8. Any other specified reason as determined by the clinical investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03389191

Layout table for location contacts
Contact: Xiaomin Zhang, M.D. +86-13920023990
Contact: Jing Yang +86-13002215386

Layout table for location information
China, Tianjin
Tianjin Medical University Eye Hospital Recruiting
Tianjin, Tianjin, China, 300000
Sponsors and Collaborators
Xiaomin Zhang
Layout table for investigator information
Study Director: Xiaomin Zhang, M.D. Tianjin Medical University Eye Hospital

Layout table for additonal information
Responsible Party: Xiaomin Zhang, MD, PhD, Tianjin Medical University Identifier: NCT03389191     History of Changes
Other Study ID Numbers: 2017KY-07
First Posted: January 3, 2018    Key Record Dates
Last Update Posted: January 3, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The study protocol,statistical analysis plan,informed consent form and clinical study report are to be shared with other researchers.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: The data will become available starting 6 months after publication.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Uveal Diseases
Eye Diseases
Antiviral Agents
Anti-Infective Agents